Human Papillomavirus Vaccines - Immune Responses

被引：125

作者：

Stanley, Margaret ^{[1
]}

Pinto, Ligia A. ^{[2
]}

Trimble, Connie ^{[3
,4
,5
]}

机构：

[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England

[2] NCI Frederick, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA

[3] Johns Hopkins Univ Hosp, Dept Obstet Gynecol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA

[5] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA

来源：

VACCINE | 2012年 / 30卷

关键词：

HPV; virus like particle; VLP; antibody; B cells; L1; protein; L2; cell mediated immunity; VIRUS-LIKE PARTICLES; HPV VACCINATION PROGRAM; INTRAEPITHELIAL NEOPLASIA; ANTIBODY-RESPONSES; NATURAL-HISTORY; YOUNG-WOMEN; T-CELLS; INFECTION; L1; TYPE-16;

D O I：

10.1016/j.vaccine.2012.04.106

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines are highly effective. The available evidence suggests that neutralising antibody is the mechanism of protection. However, despite the robust humoral response elicited by VLP vaccines, there is no immune correlate, no minimum level of antibody, or any other immune parameter, that predicts protection against infection or disease. The durability of the antibody response and the importance of antibody isotype, affinity and avidity for vaccine effectiveness are discussed. Once infection and disease are established, then cellular immune responses are essential to kill infected cells. These are complex processes and understanding the local mucosal immune response is a prerequisite for the rational design of therapeutic HPV vaccines. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Published by Elsevier Ltd.

引用

页码：F83 / F87

页数：5

共 53 条

[31] Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens [J].

Nakagawa, M ;

Stites, DP ;

Patel, S ;

Farhat, S ;

Scott, M ;

Hills, NK ;

Palefsky, JM ;

Moscicki, AB .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02) :595-598

[32] Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial [J].

Paavonen, Jorma ;

Jenkins, David ;

Bosch, F. Xavier ;

Naud, Paulo ;

Salmeron, Jorge ;

Wheeler, Cosette M. ;

Chow, Song-Nan ;

Apter, Dan L. ;

Kitchener, Henry C. ;

Castellsague, Xavier ;

de Carvalho, Newton S. ;

Skinner, S. Rachel ;

Harper, Diane M. ;

Hedrick, James A. ;

Jaisamrarn, Unnop ;

Limson, Genara A. M. ;

Dionne, Marc ;

Quint, Wim ;

Spiessens, Bart ;

Peeters, Pascal ;

Struyf, Frank ;

Wieting, Susan L. ;

Lehtinen, Matti O. ;

Dubin, Gary .

LANCET, 2007, 369 (9580) :2161-2170

[33] Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [J].

Paovonen, J. ;

Naud, P. ;

Salmeron, J. ;

Wheeler, C. M. ;

Chow, S-N ;

Apter, D. ;

Kitchener, H. ;

Castellsague, X. ;

Teixeira, J. C. ;

Skinner, S. R. ;

Hedrick, J. ;

Jaisamrarn, U. ;

Limson, G. ;

Garland, S. ;

Szarewski, A. ;

Romanowski, B. ;

Aoki, F. Y. ;

Schwarz, T. F. ;

Poppe, W. A. J. ;

Bosch, F. X. ;

Jenkins, D. ;

Hardt, K. ;

Zahaf, T. ;

Descamps, D. ;

Struyf, F. ;

Lehtinen, M. ;

Dubin, G. .

LANCET, 2009, 374 (9686) :301-314

[34] The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme [J].

Read, Tim R. H. ;

Hocking, Jane S. ;

Chen, Marcus Y. ;

Donovan, Basil ;

Bradshaw, Catriona S. ;

Fairley, Christopher K. .

SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (07) :544-547

[35] Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan [J].

Roberts, Jeffrey N. ;

Buck, Christopher B. ;

Thompson, Cynthia D. ;

Kines, Rhonda ;

Bernardo, Marcelino ;

Choyke, Peter L. ;

Lowy, Douglas R. ;

Schiller, John T. .

NATURE MEDICINE, 2007, 13 (07) :857-861

[36] Effect of Pap Smear Collection and Carrageenan on Cervicovaginal Human Papillomavirus-16 Infection in a Rhesus Macaque Model [J].

Roberts, Jeffrey N. ;

Kines, Rhonda C. ;

Katki, Hormuzd A. ;

Lowy, Douglas R. ;

Schiller, John T. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (09) :737-743

[37]

Ruiz Wanda, 2005, J Immune Based Ther Vaccines, V3, P2, DOI 10.1186/1476-8518-3-2

[38] Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections [J].

Safaeian, Mahboobeh ;

Porras, Carolina ;

Schiffman, Mark ;

Rodriguez, Ana Cecilia ;

Wacholder, Sholom ;

Gonzalez, Paula ;

Quint, Wim ;

van Doorn, Leen-Jan ;

Sherman, Mark E. ;

Xhenseval, Valerie ;

Herrero, Rolando ;

Hildesheim, Allan .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (21) :1653-1662

[39] A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines [J].

Schiller, John T. ;

Castellsague, Xavier ;

Garland, Suzanne M. .

VACCINE, 2012, 30 :F123-F138

[40] Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature [J].

Schwarz, Tino F. ;

Leo, Oberdan .

GYNECOLOGIC ONCOLOGY, 2008, 110 (03) :S1-S10

← 1 2 3 4 5 6 →